RIMI - Repository of the Institute for Medical Research
Institute for Medical Research
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation

Authorized Users Only
2018
Authors
Santibanez, Juan
Bjelica, Sunčica
Article (Published version)
Metadata
Show full item record
Abstract
Background: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. IL-17A has emerged as a topic of interest and is under profound investigation for its involvement in several types of inflammatory-associated diseases. Objective: This review aims to present an overview of the state of the art of IL-17A role in cancer and inflammation, as well as to describe recent patents targeting IL-17A with relevant clinical and biological properties for the prevention and treatment of cancer and inflammatory diseases. Methods: Relevant information was obtained by s...earching in PubMed using IL-17A or IL-17, cancer and inflammation as keywords, while relevant patents were obtained mainly from Google Patents. Results: Literature data indicated IL-17A as important biomolecule in the physiopathology of cancer and inflammatory diseases. Whereas, novel patents (2010 to 2017) targeting IL-17A are focused mainly on describing strategies to modulate IL-17A per se, co-modulation by bispecific antibodies to blocking IL-17A and important cytokines for IL-17A functions, upstream mechanisms and compounds to regulate IL-17A expression. Conclusion: The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases.

Keywords:
Cancer / inflammation / interleukin-17A (IL-17A) / interleukin-17 Receptor A (IL-17RA) / patents / signaling / therapies
Source:
Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 2, 133-144
Publisher:
  • Bentham Science Publ Ltd, Sharjah
Funding / projects:
  • UBO
  • Phylogenetic anaysis and molecular evolution of highly variable viruses: coinfections, host-pathogene interactions (RS-175024)
  • The pathogenetic mechanism in hematological malignancies (RS-175053)

DOI: 10.2174/1574892813666180220105958

ISSN: 1574-8928

PubMed: 29468982

WoS: 000432224500001

Scopus: 2-s2.0-85048982610
[ Google Scholar ]
7
5
URI
http://rimi.imi.bg.ac.rs/handle/123456789/892
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
Institut za medicinska istraživanja
TY  - JOUR
AU  - Santibanez, Juan
AU  - Bjelica, Sunčica
PY  - 2018
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/892
AB  - Background: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. IL-17A has emerged as a topic of interest and is under profound investigation for its involvement in several types of inflammatory-associated diseases. Objective: This review aims to present an overview of the state of the art of IL-17A role in cancer and inflammation, as well as to describe recent patents targeting IL-17A with relevant clinical and biological properties for the prevention and treatment of cancer and inflammatory diseases. Methods: Relevant information was obtained by searching in PubMed using IL-17A or IL-17, cancer and inflammation as keywords, while relevant patents were obtained mainly from Google Patents. Results: Literature data indicated IL-17A as important biomolecule in the physiopathology of cancer and inflammatory diseases. Whereas, novel patents (2010 to 2017) targeting IL-17A are focused mainly on describing strategies to modulate IL-17A per se, co-modulation by bispecific antibodies to blocking IL-17A and important cytokines for IL-17A functions, upstream mechanisms and compounds to regulate IL-17A expression. Conclusion: The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Recent Patents on Anti-Cancer Drug Discovery
T1  - Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
EP  - 144
IS  - 2
SP  - 133
VL  - 13
DO  - 10.2174/1574892813666180220105958
ER  - 
@article{
author = "Santibanez, Juan and Bjelica, Sunčica",
year = "2018",
abstract = "Background: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. IL-17A has emerged as a topic of interest and is under profound investigation for its involvement in several types of inflammatory-associated diseases. Objective: This review aims to present an overview of the state of the art of IL-17A role in cancer and inflammation, as well as to describe recent patents targeting IL-17A with relevant clinical and biological properties for the prevention and treatment of cancer and inflammatory diseases. Methods: Relevant information was obtained by searching in PubMed using IL-17A or IL-17, cancer and inflammation as keywords, while relevant patents were obtained mainly from Google Patents. Results: Literature data indicated IL-17A as important biomolecule in the physiopathology of cancer and inflammatory diseases. Whereas, novel patents (2010 to 2017) targeting IL-17A are focused mainly on describing strategies to modulate IL-17A per se, co-modulation by bispecific antibodies to blocking IL-17A and important cytokines for IL-17A functions, upstream mechanisms and compounds to regulate IL-17A expression. Conclusion: The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
title = "Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation",
pages = "144-133",
number = "2",
volume = "13",
doi = "10.2174/1574892813666180220105958"
}
Santibanez, J.,& Bjelica, S.. (2018). Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation. in Recent Patents on Anti-Cancer Drug Discovery
Bentham Science Publ Ltd, Sharjah., 13(2), 133-144.
https://doi.org/10.2174/1574892813666180220105958
conv_4292
Santibanez J, Bjelica S. Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation. in Recent Patents on Anti-Cancer Drug Discovery. 2018;13(2):133-144.
doi:10.2174/1574892813666180220105958
conv_4292 .
Santibanez, Juan, Bjelica, Sunčica, "Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation" in Recent Patents on Anti-Cancer Drug Discovery, 13, no. 2 (2018):133-144,
https://doi.org/10.2174/1574892813666180220105958 .,
conv_4292 .

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB